Recognition and management of significant drug interactions in HIV patients: Challenges in using available data to guide therapy

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 712-719

  Pau, A K ^a   Boyd, S D ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CORTICOSTEROID; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL INSUFFICIENCY; ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPUTER PROGRAM; CUSHING SYNDROME; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DRUG INTERACTION; DRUG FATALITY; DRUG INFORMATION; DRUG INTERACTION; DRUG MONITORING; ERECTILE DYSFUNCTION; HEALTH CARE PERSONNEL; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUBERCULOSIS; CLINICAL COMPETENCE; CLINICAL PRACTICE; DRUG COMBINATION; DRUG LABELING; DRUG SURVEILLANCE PROGRAM; HIV INFECTIONS; INFORMATION DISSEMINATION; MEDICATION ERROR; PREVENTION AND CONTROL; RISK FACTOR; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIVIRAL AGENTS; CLINICAL COMPETENCE; DRUG INTERACTIONS; DRUG LABELING; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INFORMATION DISSEMINATION; MEDICATION ERRORS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77958493396     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.130     Document Type: Review

References (29)

1. Pau, A.K. Clinical management of drug interaction with antiretroviral agents. Curr. Opin. HIV AIDS 3, 319-324 (2008).
2. Seden, K., Back, D. & Khoo, S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J. Antimicrob. Chemother. 64, 5-8 (2009).
3. Béïque, L., Giguère, P. , la Porte, C. & Angel, J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med. 8, 335-345 (2007).
4. Guiard-Schmid, J.B., Poirier, J.M., Bonnard, P. & Meynard, J.L. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J. Acquir. Immune Defc. Syndr. 41, 393-394; author reply 394 (2006).
5. Sahlof, E.G. & Duggan, J.M. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Ann. Pharmacother. 40, 1731-1736 (2006).
6. Donato, M.T., Montero, S., Castell, J.V., Gómez-Lechón, M.J. & Lahoz, A. Validated assay for studying activity profles of human liver UGTs after drug exposure: inhibition and induction studies. Anal. Bioanal. Chem. 396, 2251-2263 (2010).
7. Wenning, L.A. et al. Efect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53, 2852-2856 (2009).
8. Murphy, M.D., O'Hearn, M. & Chou, S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis. 36, 1082-1085 (2003).
9. Martínez, E. et al. Pancreatic toxic efects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 364, 65-67 (2004).
10. Kearney, B.P., Sayre, J.R., Flaherty, J.F., Chen, S.S., Kaul, S. & Cheng, A.K. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. 45, 1360-1367 (2005).
11. Foisy, M.M., Yakiwchuk, E.M., Chiu, I. & Singh, A.E. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and futicasone: a review of the literature. HIV Med. 9, 389-396 (2008).
12. Ramanathan, R. et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. Clin. Infect. Dis. 47, e97-e99 (2008).
13. MacDonald, L., Murty, M. & Foster, B.C. Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance. Expert Opin. Drug Metab. Toxicol. 5, 563-578 (2009).
14. Jones, A.E. et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol. 66, 475-485 (2010).
15. Weiner, M. et al.; Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40, 1481-1491 (2005).
16. Dickinson, L., Khoo, S. & Back, D. Diferences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr. Opin. HIV AIDS 3, 296-305 (2008).
17. Owen, A. & Khoo, S.H. Pharmacogenetics of antiretroviral agents. Curr. Opin. HIV AIDS 3, 288-295 (2008).
18. Reyataz [prescribing information]. Princeton, NJ: Bristol-Myers Squibb, 2010.
19. Hellinger, F.J. & Encinosa, W.E. The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics 28, 23-34 (2010).
20. DeLorenze, G.N. et al. Medication error in the care of HIV/AIDS patients: electronic surveillance, confrmation, and adverse events. Med. Care 43, III63-III68 (2005).
21. Pastakia, S.D., Corbett, A.H., Raasch, R.H., Napravnik, S. & Correll, T.A. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. Ann. Pharmacother. 42, 491-497 (2008).
22. Mok, S. & Minson, Q. Drug-related problems in hospitalized patients with HIV infection. Am. J. Health. Syst. Pharm. 65, 55-59 (2008).
23. Pham, P.A. Drug-drug interaction programs in clinical practice. Clin. Pharmacol. Ther. 83, 396-398 (2008).
24. Vonbach, P. , Dubied, A., Krähenbühl, S. & Beer, J.H. Evaluation of frequently used drug interaction screening programs. Pharm. World Sci. 30, 367-374 (2008).
25. Malone, D.C. et al. Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Med. Care 45, 456-462 (2007).
26. Maartens, G., Decloedt, E. & Cohen, K. Efectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir. Ther. (Lond.) 14, 1039-1043 (2009).
27. Boulle, A. et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 300, 530-539 (2008).
28. Babb, D.A., Pemba, L., Seatlanyane, P. , Charalambous, S., Churchyard, G.J. & Grant, A.D. Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol. Health Med. 12, 314-320 (2007).
29. Evans-Jones, J.G. et al. Recognition of risk for clinically signifcant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin. Infect. Dis. 50, 1419-1421 (2010).